中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (4): 298-302.doi: 10.12144/zgmfskin202504298

• 综述 • 上一篇    下一篇

慢性自发性荨麻疹治疗进展

周思婕1,周培媚2   

  1. 1成都中医药大学医学与生命科学学院，四川成都，610075；2成都市第二人民医院皮肤科，四川成都，610000
  • 出版日期:2025-04-15 发布日期:2025-04-08

Update of the treatment for chronic spontaneous urticaria

ZHOU Sijie1, ZHOU Peimei2   

  1. 1 School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China; 2 Department of Dermatology, Chengdu Second People's Hospital, Chengdu 610000, China
  • Online:2025-04-15 Published:2025-04-08

PDF (PC)

28

摘要： 慢性自发性荨麻疹（CSU）发病机制复杂，第二代H1受体拮抗剂是其治疗首选。近年来，生物制剂如奥马珠单抗的应用显著改善了患者病情。随着对CSU发病机制的深入研究，新的治疗靶点不断涌现，包括布鲁顿酪氨酸激酶抑制剂、抗IgE单克隆抗体、脾酪氨酸激酶抑制剂、抗唾液酸结合免疫球蛋白样凝集素-8抗体等。此外，辅助治疗手段如自体血清治疗、光疗和粪便菌群移植也显示出一定的疗效。这些新药和治疗方法为CSU的治疗提供了更多选择，本文就CSU治疗进展作一综述。

关键词: 慢性自发性荨麻疹, 发病机制, 治疗, 生物制剂

Abstract: The pathogenesis of chronic spontaneous urticaria (CSU) is complex, and second-generation H1 receptor antagonists are the first choice for its treatment. In recent years, the use of biologics such as omalizumab has significantly improved patient conditions. With the further study of the pathogenesis of CSU, new therapeutic targets continue to emerge, including Bruton tyrosine kinase inhibitors, anti-IGE monoclonal antibodies, spleen tyrosine kinase inhibitors, anti-sialic-binding immunoglobulin-like lectin 8 antibody, etc. In addition, adjuvant treatments such as autologous serum therapy, phototherapy and fecal flora transplantation have also shown some efficacy. These new drugs and therapeutic methods provide more options for the treatment of CSU. This paper reviews the progress in the treatment of CSU.

Key words: chronic spontaneous urticaria, pathogenesis, treatment, biologics